SCHEMBL3576759

SCHEMBL3576759

O=[N+]([O-])c1cnccc1OCc1ccc(Cl)cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
INPPL1 O15357 2/20 0.54
LMNA P02545 1/20 0.46
S1PR4 O95977 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 2/20 0.45
HPD P32754 2/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C9 P11712 2/20 0.43
PTGER1 P34995 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
HDAC8 Q9BY41 1/20 0.42
FABP3 P05413 1/20 0.42
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
PRKCQ Q04759 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770576 0.90 INPPL1 (0.54) INPPL1LMNAS1PR4L3MBTL1KMT2A
SCHEMBL3578915 0.82 MEN1 (0.48) LMNAKMT2ANPC1RAB9A
SCHEMBL16295426 0.79 SLC6A2 (0.52) LMNAS1PR4TSHRMAPK1
SCHEMBL11702333 0.78 S1PR4 (0.51) INPPL1LMNAS1PR4HPDTSHR
SCHEMBL11699501 0.77 LMNA (0.71) INPPL1LMNAS1PR4L3MBTL1KMT2A
SCHEMBL11703752 0.77 S1PR4 (0.50) INPPL1LMNAS1PR4L3MBTL1KMT2A
SCHEMBL16295605 0.76 HPGD (0.47) LMNATSHRMAPK1RAB9A
SCHEMBL5797850 0.76 MAPT (0.50) INPPL1LMNAS1PR4L3MBTL1KMT2A
SCHEMBL488306 0.76 S1PR4 (0.71) LMNAS1PR4L3MBTL1KMT2AHPD
SCHEMBL11704760 0.75 ALDH1A1 (0.62) LMNAKMT2ATSHRMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784403-B1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2013-07-17 EP disclosed
US-7642269-B2 Pyrrolo[3,2-B]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2010-01-05 US disclosed
US-20070213358-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2007-09-13 US disclosed
EP-1784403-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2007-05-16 EP disclosed
WO-2007001139-A1 A COMPOSITION FOR TREATING OR PREVENTING A CANCER COMPRISING PYRROLOPYRIDINE DERIVATIVES YUHAN CORPORATION (KR) 2007-01-04 WO disclosed
WO-2006038773-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213358-A1 PYRROLO[3,2-B]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF PGA5, ATP6AP1, PPOX INPPL1 547/4885LMNA 4407/4885S1PR4 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.